Compare Teucrium Soybean Fund (SOYB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs TG Therapeutics Inc — how do they compare? Teucrium Soybean Fund trades at $25.33, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SOYB | TGTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $26.28 | $59.06 |
52-Week Low | $21.46 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $25.24, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights agricultural sector tailwinds from China's crop purchase pledge, though geopolitical risks from Middle East tensions pose headwinds.
The outlook hinges on sector-specific catalysts like export demand, but absent financial data obscures valuation. Risks include commodity volatility and geopolitical spillovers. Investors require updated SEC filings to assess profitability and growth prospects amid mixed technical signals.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
